|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myxoid liposarcoma with cartilaginous differentiation: identification of the same type II TLS-CHOP fusion gene transcript in both lipogenic and chondroid components.
|
18091394 |
2007 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myxoid/round-cell liposarcoma (MLS/RCLS) is characterized by either the fusion gene FUS-DDIT3 or the less commonly occurring EWSR1-DDIT3 and most cases carry few or no additional cytogenetic changes.
|
25393000 |
2014 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS-DDIT3 in myxoid liposarcoma) and specific oncogenic mutations (e.g.
|
16359533 |
2006 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS-DDIT3 dependency and biological function of the IGF-IR/PI3K/Akt signaling cascade were analyzed using a HT1080 fibrosarcoma-based myxoid liposarcoma tumor model and multiple tumor-derived myxoid liposarcoma cell lines.
|
28637688 |
2017 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
|
29190494 |
2018 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An amplification of the MDM2 and CDK4 genes respectively in the atypical lipomatous tumor/well-differentiated liposarcoma areas was detected by fluorescence in situ hybridization (FISH) analysis, and translocations of the CHOP and FUS genes were detected by FISH analysis in the myxoid/round cell liposarcoma areas.
|
18551309 |
2008 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blocking of this pathway by TLS-CHOP may play a mechanistic role in the establishment of myxoid liposarcoma.
|
8125258 |
1994 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Described here is the use of detecting TLS/FUS-CHOP fusion transcripts to confirm the diagnosis of a myxoid liposarcoma by nested reverse transcription-polymerase chain reaction assay using archival formalin-fixed, paraffin-embedded tissues of a young man with a benign-looking myxoid tumor on his upper extremity, which is often misdiagnosed clinically or histopathologically as a benign tumor.
|
12930346 |
2003 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay.
|
20581806 |
2010 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downstream of the gene for the liposarcoma-associated fusion oncoprotein 54 (DOL54) is a target gene of the myxoid liposarcoma and round cell liposarcoma (M-LPS/RC-LPS) oncogene, TLS/FUS-CHOP.
|
12366807 |
2002 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor.
|
21403840 |
2011 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
|
27270875 |
2016 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EWS in 22q12 has a very high homology with FUS (also called TLS) in 16p11; the latter gene is rearranged in the t(12;16)(q13;p11) that characterizes myxoid liposarcoma.
|
7533529 |
1994 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we studied a subgroup of sarcomas and leukaemias characterized by the FET (FUS, EWSR1, TAF15) family of fusion oncogenes, including FUS-DDIT3 in myxoid liposarcoma (MLS).
|
26865464 |
2016 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human myxoid liposarcoma contains a characteristic t(12;16) chromosomal translocation that results in fusion of the N-terminal domain of the translocated in liposarcoma (TLS) protein to the C/EBP homologous protein (CHOP).
|
12168660 |
2002 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, interphase FISH using DDIT3 and FUS probes identifies the characteristic translocation in myxoid liposarcoma.
|
18162764 |
2008 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the case of myxoid liposarcoma (MLS) tumors, the causative abnormality is a fusion between the CHOP transcription factor and the FUS or EWS genes.
|
19190116 |
2009 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
|
26897615 |
2016 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRG4 is one of the downstream molecules of the myxoid liposarcoma (MLS)-specific fusion oncoproteins TLS-CHOP and EWS-CHOP.
|
28192118 |
2017 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the total number of patients is still limited, further studies are required to verify a putative association of type I FUS/DDIT3-fusion transcripts with a prognosis of MRCL.
|
17647282 |
2007 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, endogenous mesenchymal stem cells (MSCs) expressing TLS:CHOP developed into MRCLS in vivo.
|
22293175 |
2012 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our observations suggest that expression of FUS-CHOP may be the initiating event in myxoid liposarcoma pathogenesis, and that MPCs may constitute one cell type from which these tumors originate.
|
16849546 |
2006 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies.
|
11802205 |
2002 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The myxoid/round cell liposarcoma oncogene FUS-DDIT3 is the result of a translocation derived gene fusion between the splicing factor FUS and DDIT3.
|
15688424 |
2005 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
|
16651630 |
2006 |